Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing,, China
Case Report
Relma-cel Elicited Durable Remission in a r/r MCL Patient with High-Risk Factors: A Case Report
Author(s): Yan Xie, Yuqin Song and Jun Zhu*
Relapsed/refractory (r/r) Mantle Cell Lymphoma (MCL) is a subtype of mature B-cell lymphoma and characterized by heterogenous and aggressive clinical behaviors. Patients treated with conventional agents have a poor prognosis, especially those who have failed BTKi treatment, indicating a high unmet need for novel therapies. Chimeric Antigen Receptor (CAR) T-cell therapy has been approved for the treatment of r/r hematologic malignancies. In this case, we present a patient with MCL who exhibited many poor risk features, such as a high tumor burden with a Sum of Product of Diameters (SPD) of 19124 mm2, serous cavity effusion, and extensive treatment with systematic therapies. After failing multiple lines of systemic chemotherapies, autologous stem-cell transplantation, and treatment with the BTK inhibitor (ibrutinib), the patient received a single dose of 100 × 106.. View More»
DOI:
10.35248/2471-8556.24.10(1).003